摘要:
This invention relates to a transdermal patch in the form of a layer complex, comprising a backing layer, a drug-reservoir layer comprising pharmacologically active ingredients and pharmaceutically acceptable adjuvants, and a release liner covering the drug-reservoir layer, characterized in that the drug-reservoir layer comprises isosorbide dinitrate and Bisoprolol at a ratio of 1:3 to 3:1 by weight, as the pharmacologically active ingredients. Animal tests show that said patch can reduce the elevation of T wave of cardiogram, the increase of the level of myocardial enzyme in blood serum, and the extension of the range of myocardial infarction caused by ligating the coronary artery in animals. Results show that said patch exhibits a considerable synergistic effect in the treatment of cardiovascular diseases and has good preventive and therapeutic effects on several adverse events on heart. In addition, the animal tests show that the patch according to the invention has a better pressure-reducing effect than the application of the patch containing only one of isosorbide dinitrate and Bisoprolol, and does not worsen the arrhythmia that is easily caused by the application of the patch containing only isosorbide dinitrate or Bisoprolol.
摘要:
This invention relates to a transdermal patch in the form of a layer complex, comprising a backing layer, a drug-reservoir layer comprising pharmacologically active ingredients and pharmaceutically acceptable adjuvants, and a release liner covering the drug-reservoir layer, characterized in that the drug-reservoir layer comprises isosorbide dinitrate and Bisoprolol at a ratio of 1:3 to 3:1 by weight, as the pharmacologically active ingredients. Animal tests show that said patch can reduce the elevation of T wave of cardiogram, the increase of the level of myocardial enzyme in blood serum, and the extension of the range of myocardial infarction caused by ligating the coronary artery in animals. Results show that said patch exhibits a considerable synergistic effect in the treatment of cardiovascular diseases and has good preventive and therapeutic effects on several adverse events on heart. In addition, the animal tests show that the patch according to the invention has a better pressure-reducing effect than the application of the patch containing only one of isosorbide dinitrate and Bisoprolol, and does not worsen the arrhythmia that is easily caused by the application of the patch containing only isosorbide dinitrate or Bisoprolol.
摘要:
The present invention relates to a composition containing Rotigotine and the use thereof in the manufacture of a Rotigotine-containing transdermal patch, wherein said composition is based on a matrix mixture system formed from a combination of an acrylic pressure-sensitive adhesive with a silicone pressure-sensitive adhesive, and polyvinylpyrrolidone which are present in a particular weight ratio, wherein (1) the acrylic pressure-sensitive adhesive is present in an amount of about 1-25% by weight in the matrix mixture system, (2) the silicone pressure-sensitive adhesive is present in an amount of about 65-98% by weight in the matrix mixture system, and (3) the polyvinylpyrrolidone is present in an amount of about 1-10% by weight in the matrix mixture system, and comprises 1-40% of Rotigotine on the basis of the total weight of the composition. The present invention further relates to an improved transdermal patch containing Rotigotine comprising said composition. Said patch has improved properties in the solubility, release and initial penetration level of Rotigotine.
摘要:
A Rotigotine-containing composition having a matrix mixture system formed from a polyvinylpyrrolidone and a combination of an acrylic pressure-sensitive adhesive with a silicone pressure-sensitive adhesive. The polyvinylpyrrolidone may be present in an amount of about 1-10% by weight in matrix mixture system. The acrylic pressure-sensitive adhesive may be present in an amount of about 1-25% by weight in the matrix mixture system. The silicone pressure-sensitive adhesive may be present in an amount of about 65-98% by weight in the matrix mixture system. The composition further includes 1-40% of Rotigotine on the basis of the total weight of the composition. The composition provides improved properties in the solubility, release and initial penetration level of Rotigotine. Also disclosed is a transdermal patch that includes the Rotigotine-containing composition, as well as methods of manufacturing and using the Rotigotine-containing composition.
摘要:
There is provided a method for treating the surface of metals such as nickel based or high alloy steels, austenitic and ferritic stainless steels, copper and aluminum alloys to increase their corrosion resistance by modification of the metal surfaces to inhibit cathodic corrosion processes. In a single step treatment process the metals are immersed into a heated aqueous composition containing a rare earth salt substantially free of any halide compound. Increased corrosion resistance is obtained using nitrates of yttrium, gadolinium, cerium, europium, terbium, samarium, neodymium, praseodymium, lanthanum, holmium, ytterbium, dysprosium, and erbium nitrates. The rare earth salt is present in the range from about 2% by weight to saturation of the solution. The composition includes a pH-modifying substance such as nitric acid to adjust the pH in the range 0.5 to about 6.5 to attack the surface to remove oxides facilitating deposition of the rare earth.
摘要:
There is provided a method for treating the surface of metals such as nickel based or high alloy steels, austenitic and ferritic stainless steels, copper and aluminum alloys to increase their corrosion resistance by modification of the metal surfaces to inhibit cathodic corrosion processes. In a single step treatment process the metals are immersed into a heated aqueous composition containing a rare earth salt substantially free of any halide compound. Increased corrosion resistance is obtained using nitrates of yttrium, gadolinium, cerium, europium, terbium, samarium, neodymium, praseodymium, lanthanum, holmium, ytterbium, dysprosium, and erbium nitrates. The rare earth salt is present in the range from about 2% by weight to saturation of the solution. The composition includes a pH-modifying substance such as nitric acid to adjust the pH in the range 0.5 to about 6.5 to attack the surface to remove oxides facilitating deposition of the rare earth. For aluminum alloys the pH is maintained between 4.5 to 6.5, for nickel based alloys and austenitic stainless steels the pH is maintained between 0.5 to 3.5 and between pH 2.0 to 4.5 for ferritic stainless steels. The surface can also be conditioned by abrasion before or during immersion in the composition. Increased corrosion resistance is achieved by immersion for time periods in the range of a few minutes up to one hour with the composition maintained between 60 to 95.degree. C. Cerium, gadolinium, neodymium and praseodymium nitrate when used alone produced the greatest degree of corrosion resistance compared to the other rare earth nitrates. Significant synergistic effects are observed when combinations of two or more rare earth nitrates are used in the compositions. Aqueous treatment solutions based on combinations of cerium nitrate, gadolinium nitrate and lanthanum nitrate are very effective in reducing crevice corrosion.